GU Cancers 2026 | Late effects and cognitive outcomes in RCC: insights from RAMPART trial
Sophie Merrick, MBCHB, MRCP, University College London, London, UK, comments on the emergence of late effects in patients with renal cell carcinoma in the RAMPART trial (NCT03288532), including cognitive function, which is evaluated through self-reported questionnaires and may not always correlate with objective cognitive impairment. These late effects are important to consider in patients who have completed treatment, particularly in the context of the toxicity pattern observed with durvalumab and tremelimumab. This interview took place at the 2026 ASCO GU Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We really saw this kind of initial worsening at week 16 in lots of different areas, and we did see improvement over time, but we did see these new kind of late emerging effects. And in terms of tolerability, I guess that fits with the toxicity pattern that we were seeing with durvalumab and tremelimumab, and we’re kind of expecting, given the grade 3 adverse events and treatment discontinuation that we saw in that arm...
We really saw this kind of initial worsening at week 16 in lots of different areas, and we did see improvement over time, but we did see these new kind of late emerging effects. And in terms of tolerability, I guess that fits with the toxicity pattern that we were seeing with durvalumab and tremelimumab, and we’re kind of expecting, given the grade 3 adverse events and treatment discontinuation that we saw in that arm. But I think those late effects, there’s a couple of points to say there. Firstly, cognitive function is evaluated by a questionnaire that’s self-reported. So it doesn’t necessarily always correlate with objective cognitive impairment. But nevertheless, it’s important to think about late effects in these patients who’ve completed treatment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
